Last Updated on October 14, 2024 by The Health Master
The U.S. Food and Drug Administration (USFDA) has approved Pfizer Inc’s (PFE.N) drug to treat hair loss caused by an autoimmune disease, the company said.
The drug, branded as Litfulo, has been approved for people aged 12 years and older suffering from severe alopecia areata (AA), a condition where the immune system attacks hair follicles and causes hair to fall out, often in clumps.
The USFDA’s decision makes Litfulo the first to be allowed for the treatment of the condition in adolescents.
The drug, which will be available in the coming weeks, is also the second systemic treatment to gain approval after Eli Lilly’s (LLY.N) Olumiant, used to treat the condition in adults.
“AA affects people of all ages, and not uncommonly, it affects adolescent and younger population, so to have an approved agent for adolescent is a significant leap forward,” said Brett King, associate professor of dermatology at Yale School of Medicine, ahead of the decision.
Systemic treatments usually target the cause of the disease and impact the entire body’s function including the immune system. Other treatments for alopecia areata – which include oral steroids and topical medications – target only certain affected parts of the body.
AA affects 300,000 people in the U.S. each year. It gained increased attention after actor and talk show host Jada Pinkett Smith, who suffers from the condition, was at the center of a controversy at the Academy Awards in 2022.
Pfizer could price its product competitively with Olumiant, BMO Capital analyst Keith Tapper said before the approval.
Olumiant has a list price of $2,622 for a 30-day supply of 2-microgram tablets or $5,244 for a 30-day supply of 4-microgram tablets, according to Lilly’s website.
Pfizer’s application to the USFDA was based on data from a mid- to late-stage study that showed 80% or more hair coverage after six months of using the drug compared to a placebo.
USFDA gives approval for Tiotropium dry powder inhaler
USFDA gives approval for generic acne-treating drug
USFDA gives final nod for Varenicline Tablets
USFDA gives approval for Levetiracetam Tablets
NMC releases draft Regulations for Maintaining Standards of Medical Education in India
DTAB: Proposal to restrict Nicotine Replacement Therapies Sales to Prescription Only
USFDA gives approval for Tiotropium dry powder inhaler
Govt contemplates divesting Stake in Pharma Sector PSUs
India plans to establish Self-Regulatory Body for Pharma Industry
Advantages and Integration of Pharma Sahi Daam App: Karnataka
Govt Job: For the post of Drugs Inspector under Public Service Commission
Zydus Lifesciences gets USFDA nod for generic acne-treating drug
German pharma major Bayer stops business in Pakistan: Report
Importance of Quality and Regulations in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
